BioSpace News Archive

Deals

Zogenix Buys Modis in $400 Million-Plus Deal to Make Larger Rare Disease Company

“This transaction advances Zogenix’s mission to become a leading rare disease pharmaceutical company by adding MT1621 to our pipeline of late-stage Fintepla programs,” stated Stephen J. Farr, president and chief executive officer of Zogenix.

August 26, 2019

·

3 min read

·

Mark Terry

Biotech Beach

New Gene-Editing Tool, SATI, Focuses on Non-Coding Regions of the Genome

Researchers with the Salk Institute developed a new type of gene editing called SATI that may provide the option of editing numerous gene mutation diseases like Huntington’s disease and the rare premature aging syndrome, progeria.

August 26, 2019

·

2 min read

·

Mark Terry

BioMidwest

Abbott Blood Test Can Detect Concussions that CT Scans Missed, Study Shows

It is estimated that nearly 5 million people visit the emergency room each year for a suspected concussion. However, about half of all concussions go undetected with current standard-of-care analysis, including CT scans.

August 26, 2019

·

2 min read

·

Alex Keown

Biotech Bay

MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019

MyoKardia, Inc. announced the presentation of three abstracts at the upcoming European Society of Cardiology Congress taking place August 31 – September 4, 2019 in Paris, France.

August 26, 2019

·

2 min read

Pictured: Pile of money/iStock, Ihor Lukianenko

Biotech Beach

BMS and Celgene Merger Moves Forward with $13.4 Billion Sale of Otezla

BMS and Celgene first announced the probable sale of the asset earlier this summer as a means to smooth out the anti-trust review process of the merger from the Federal Trade Commission.

August 26, 2019

·

3 min read

·

Alex Keown

Drug Development

In Extensive Clinical Tests, Olumiant Continues to Show Efficacy in Atopic Dermatitis

The investigational JAK inhibitor has hit the mark in three late-stage studies, with readouts from two more late-stage trials expected later this year.

August 26, 2019

·

2 min read

·

Alex Keown

Drug Development

The Medicines Company’s PCSK9 Inhibitor for Cholesterol Looks Good in Phase III

Inclisiran is a PCSK9 inhibitor, a class of anti-cholesterol medications used to treat patients who don’t respond to statins.

August 26, 2019

·

2 min read

·

Mark Terry

Analysis Provides Snapshot of Growth Revenue in Top 20 Publicly Traded Pharma Companies

In terms of revenue generation, 2018 was a good year for the pharmaceutical industry, with 16 of the top 20 publicly traded companies posting year-on-year growth in revenue.

August 26, 2019

·

2 min read

·

Alex Keown